Genmab AS (MEX:GMAB1N) Cyclically Adjusted FCF per Share: MXN16.43 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GMAB1N Genmab AS MEX:GMAB1N
100 GF Score
Price MXN465.00
GF Value MXN529.26
! 5 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted FCF per Share?

Genmab AS MEX:GMAB1N 100 Cyclically Adjusted FCF per Share is MXN16.43 as of Jun. 2026. GuruFocus rates MEX:GMAB1N with a GF Score™ of 100/100 and a GF Value™ of MXN529.26. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Genmab AS's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN1.357. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN16.43 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Genmab AS's average Cyclically Adjusted FCF Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 32.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 34.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Genmab AS was 110.70% per year. The lowest was 32.70% per year. And the median was 52.10% per year.

As of today (2026-08-08), Genmab AS's current stock price is MXN465.00. Genmab AS's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN16.43. Genmab AS's Cyclically Adjusted Price-to-FCF of today is 28.30.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Genmab AS was 24633.33. The lowest was 22.87. And the median was 131.71.


Genmab AS  (MEX:GMAB1N) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Genmab AS's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=465.00/16.43
=28.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Genmab AS was 24633.33. The lowest was 22.87. And the median was 131.71.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Genmab AS Cyclically Adjusted FCF per Share Related Terms


Genmab AS Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted FCF per Share Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genmab AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 16.43

MEX:GMAB1N vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted Price-to-FCF falls into.


MEX:GMAB1N
100GF Score
Genmab AS MEX:GMAB1N
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.357/122.9700*122.9700
=1.357

Current CPI (Jun. 2026) = 122.9700.

Genmab AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.963 100.200 1.182
201612 -0.604 100.300 -0.741
201703 3.268 101.200 3.971
201706 2.498 101.200 3.035
201709 0.229 101.800 0.277
201712 1.279 101.300 1.553
201803 2.107 101.700 2.548
201806 0.430 102.300 0.517
201809 -0.917 102.400 -1.101
201812 0.859 102.100 1.035
201903 2.970 102.900 3.549
201906 0.825 102.900 0.986
201909 1.077 102.900 1.287
201912 0.731 102.900 0.874
202003 9.772 103.300 11.633
202006 0.704 103.200 0.839
202009 27.034 103.500 32.120
202012 -2.659 103.400 -3.162
202103 5.649 104.300 6.660
202106 1.417 105.000 1.660
202109 1.617 105.800 1.879
202112 0.606 106.600 0.699
202203 2.401 109.900 2.687
202206 3.658 113.600 3.960
202209 7.250 116.400 7.659
202212 2.370 115.900 2.515
202303 12.549 117.300 13.156
202306 1.213 116.400 1.281
202309 6.868 117.400 7.194
202312 6.491 116.700 6.840
202403 5.464 118.400 5.675
202406 6.073 118.500 6.302
202409 9.026 118.900 9.335
202412 11.597 118.900 11.994
202503 8.224 120.200 8.414
202506 1.579 120.700 1.609
202509 15.781 121.600 15.959
202512 8.216 121.200 8.336
202603 -0.056 121.680 -0.057
202606 1.357 122.970 1.357

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN16.43 mean?
Genmab AS (MEX:GMAB1N) has a Cyclically Adjusted FCF per Share of MXN16.43 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Genmab AS and its competitors.
Is Genmab AS's Cyclically Adjusted FCF per Share too high?
Genmab AS's current Cyclically Adjusted FCF per Share is MXN16.43. Overall, Genmab AS has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Genmab AS's Cyclically Adjusted FCF per Share of MXN16.43 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Genmab AS and its competitors. Genmab AS's current Cyclically Adjusted FCF per Share is MXN16.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Genmab AS (MEX:GMAB1N) has a current Cyclically Adjusted FCF per Share of MXN16.43. The stock's GF Value™ is MXN529.26, compared to a current price of MXN465.00 — trading 12.1% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN16.43. Genmab AS's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Genmab AS (MEX:GMAB1N), the current Cyclically Adjusted FCF per Share is MXN16.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (MEX:GMAB1N) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of MXN465.00 is trading 12.1% below its estimated GF Value™ of MXN529.26.

Key valuation signals for MEX:GMAB1N:

  • Cyclically Adjusted FCF per Share: MXN16.43
  • GF Value™: MXN529.26 vs. price of MXN465.00 (12.1% below fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the MEX:GMAB1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
100GF Score

Get the complete analysis for MEX:GMAB1N

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN465.00
Price
MXN529.26
GF Value